sefulness of using C-11 methionine PET in patient which suspected glioma
Not Applicable
- Conditions
- glioma
- Registration Number
- JPRN-UMIN000022067
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Not provided
Exclusion Criteria
(1)The patients with a history of allergic reaction to C-11 methionine or F-18 FDG. (2)Pregnant women, breast-feeding women, or women who may be pregnant (3)The patients who is participating in other trials (4)The patients who underwent C-11 methionine PET within 90 days (5)The patients whose overall status is not satisfactory for surgical treatment (6) The patients who cannot undergo contrast-enhanced MRI (7) The patients whom investigators judged to be inadequate as candidates
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive-predictive value (PPV) in the site of negative contrast-enhanced MRI and positive Met-PET which assume a histopathology diagnosis criteria diagnosis.
- Secondary Outcome Measures
Name Time Method (1) Rate of cases where Met-PET positive area is equivalent to MRI enhanced area (2)Rate of cases where tumor exists in the area of MRI-positive and Met-PET-negative findings. (3)Safety: Presence/absence and details of the adverse event, including abnormal changes of vital signs and laboratory data.